Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease

Coronary Artery Disease

Volumn 16, Issue 7, 2005, Pages 443-449

  Tawakol, Ahmed ^a   Aziz, Kusai ^a   Migrino, Raymond ^a   Watkowska, Justyna ^a   Zusman, Randall ^a   Alpert, Nathaniel M ^a   Fischman, Alan J ^a   Gewirtz, Henry ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Ischemic heart disease; Myocardial blood flow; Sildenafil

Indexed keywords

ADENOSINE; PLACEBO; SILDENAFIL;

ADULT; AGED; ARTICLE; BLOOD FLOWMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART HEMODYNAMICS; HEART MUSCLE BLOOD FLOW; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CORONARY CIRCULATION; CORONARY VESSELS; DOUBLE-BLIND METHOD; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; VASODILATOR AGENTS;

EID: 27344442599     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200510000-00005     Document Type: Article

References (24)

1. Halcox J P, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40:1232-1240.
2. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342:1622-1626.
3. Tawakol A, Skopicki HA, Abraham SA, Alpert NM, Fischman AJ, Picard MH, et al. Evidence of reduced resting blood flow in viable myocardial regions with chronic asynergy. J Am Coll Cardiol 2000; 36:2146-2153.
4. Tawakol A, Forgione MA, Stuehlinger M, Alpert NM, Cooke JP, Loscalzo J, et al. Homocysteine impairs coronary microvascular dilator function in humans. J Am Coll Cardiol 2002; 40:1051-1058.
5. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse [see comments]. Circulation 1998; 98:1291-1296.
6. Skopicki HA, Abraham SA, Picard MH, Alpert NM, Fischman AJ, Gewirtz H. Effects of dobutamine at maximally tolerated dose on myocardial blood flow in humans with ischemic heart disease [published erratum appears in Circulation 97:414]. Circulation 1997; 96:3346-3352.
7. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990; 15:1032-1042.
8. Gewirtz H, Skopicki HA, Abraham SA, Castano H, Dinsmore RE, Alpert NM, et al. Quantitative PET measurements of regional myocardial blood flow: observations in humans with ischemic heart disease. Cardiology 1997; 88:62-70.
9. Tawakol A, Sims K, MacRae C, Friedman JR, Alpert NM, Fischman AJ, et al. Myocardial flow regulation in people with mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes/myoclonic epilepsy and ragged red fibers and other mitochondrial syndromes. Coron Artery Dis 2003; 14:197-205.
10. Senneff MJ, Hartman J, Sobel BE, Geltman EM, Bergmann SR. Persistence of coronary vasodilator responsivity after cardiac transplantation. Am J Cardiol 1993; 71:333-338.
11. Folland E, Vogel R, Hartigan P, Bates E, Beauman G, Fortin T, et al. Investigators VA. Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single-vessel coronary artery disease. Circulation 1994; 89:2005-2014.
12. Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, Schafers KP, Luscher TF, Camici PG. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 2000; 102:1233-1238.
13. De Bruyne B, Pijls NH, Barbato E, Bartunek J, Bech JW, Wijns W, et al. Intracoronary and intravenous adenosine 5′-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation 2003; 107:1877-1883.
14. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 2001; 104:2305-2310.
15. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000; 101:689-694.
16. Williams DO, Most AS. Responsiveness of the coronary circulation to brief versus sustained alpha adrenergic stimulation. Circulation 1981; 63:11-16.
17. Canty JM Jr, Schwartz JS. Nitric oxide mediates flow-dependent epicardial coronary vasodilation to changes in pulse frequency but not mean flow in conscious dogs. Circulation 1994; 89:375-384.
18. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease (review). Circulation 1995; 92:2333-2342.
19. Conti CR. Why we should attempt to eliminate (silent and symptomatic) ischemia in patients with chronic stable angina. Clin Cardiol 1998; 21:118-1111.
20. Pepine CJ, Feldman RL, Ludbrook P, Holland P, Lambert CR, Conti CR, et al. Left ventricular dyskinesia reversed by intravenous nitroglycerin: a manifestation of silent myocardial ischemia. Am J Cardiol 1986; 58:38B-42B.
21. Lambert CR Jr, Conti CR, Pepine CJ. Left ventricular function abnormalities as a manifestation of silent myocardial ischemia. Cardiol Clin 1986; 4:669-675.
22. Fallavollita J, Canty JJ. Differential 18-F-2-deoxyglucose uptake in viable dysfunctional myocardium with normal resting perfusion: evidence for chronic stunning in pigs. Circulation 1999; 99:2798-2805.
23. Agelink MW, Ullrich H, Brockmeyer NH. Sildenafil does not influence autonomic neurocardiac control assessed by standard measurements of heart rate variability. Circulation 2001; 104:E145.
24. Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40:2006-2012.